Basic info
Industry
biotechnology research
Sectors
first-in-target
Biotechnology
hyperhomocysteinemia
neurodegenerative disease
rare disease
neuromuscular disease
mitochondrial disease
muscular dystrophy
mitochondrial myopathy
drug discovery
preclinical
Duchenne
DMD
mitochondria
Huntington's disease
first-in-class
Therapeutics
dementia
MTRX-1
new class
MitoRx
CBS-deficiency
Huntington's
biotech
Date founded
2021
Funding rounds raised
M
MitoRx Therapeutics raised undisclosed on April 25, 2022
Investors: Future Planet Capital, UK Innovation & Science Seed Fund, Wren Capital LLP, Longevitytech.fund, Science Angel Syndicate, Oxford Technology Management and Fink Family Office
M
MitoRx Therapeutics raised undisclosed on March 1, 2019
Investors: Future Planet Capital